Browsing St. Olavs hospital by Author "Waterloo, Knut"

Now showing items 1-6 of 6

    • Demographically adjusted trail making test norms in a Scandinavian sample from 41 to 84 years 

      Espenes, Johan Jacob; Hessen, Erik; Eliassen, Ingvild Vøllo; Waterloo, Knut; Eckerström, Marie; Sando, Sigrid Botne; Timón, Santiago; Wallin, Anders; Fladby, Tormod; Kirsebom, Bjørn-Eivind (Peer reviewed; Journal article, 2020)
      Objective The trail making test (TMT) is one of the most widely used neuropsychological tests. TMT-A provides measures of visual scanning/visuomotor speed and TMT-B involves additional demands on executive functions. ...

    • Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind Seljelid; Richter, Grit; Pålhaugen, Lene; Gisladottir, Berglind; Siafarikas, Nikias Ioannis; Nakling, Arne Exner; Rongve, Arvid; Bråthen, Geir; Grøntvedt, Gøril Rolfseng; Gonzalez, Fernando; Waterloo, Knut; Sharma, Kulbhushan; Karikari, Thomas; Vromen, Eleonora M.; Tijms, Betty M.; Visser, Pieter J.; Selnes, Per; Kramberger, Milicia G.; Winblad, Bengt; Blennow, Kaj; Fladby, Tormod (Peer reviewed; Journal article, 2023)
      Background Brain innate immune activation is associated with Alzheimer’s disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal ...

    • Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease 

      Gonzalez-Ortiz, Fernando; Kirsebom, Bjørn-Eivind Seljelid; Contador, José; Tanley, Jordan E.; Selnes, Per; Gisladottir, Berglind; Pålhaugen, Lene; Hemminghyth, Mathilde Suhr; Jarholm, Jonas Alexander; Skogseth, Ragnhild Eide; Bråthen, Geir; Grøndtvedt, Gøril; Bjørnerud, Atle; Tecelao, Sandra; Waterloo, Knut; Aarsland, Dag; Fernández-Lebrero, Aida; García-Escobar, Greta; Navalpotro-Gómez, Irene; Turton, Michael; Hesthamar, Agnes; Kac, Przemyslaw R.; Nilsson, Johanna; Luchsinger, Jose; Hayden, Kathleen M.; Harrison, Peter; Puig-Pijoan, Albert; Zetterberg, Henrik; Hughes, Timothy M.; Suárez-Calvet, Marc; Karikari, Thomas K.; Fladby, Tormod; Blennow, Kaj (Journal article; Peer reviewed, 2024)
      Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer’s disease (AD). In blood, phosphorylated tau (p-tau) associates ...

    • Regression-Based Cognitive Change Norms Applied in Biochemically Defined Predementia Alzheimer’s Disease 

      Eliassen, Ingvild Vøllo; Kirsebom, Bjørn-Eivind; Fladby, Tormod; Waterloo, Knut; Sando, Sigrid Botne; Hemminghyth, Mathilde Suhr; Aarsland, Dag; Reina, Santiago Timon; Wallin, Anders; Öhman, Fredrik; Eckerström, Marie; Hessen, Erik (Peer reviewed; Journal article, 2022)
      Objective: We aim to develop 2-year cognitive change norms for adults ages 41–84 for six cognitive tests, and to evaluate these norms in groups with AD biomarkers. Background: Practice effects are common in repeated ...

    • Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample 

      Lorentzen, Ingrid Myrvoll; Espenes, Johan Jacob; Hessen, Erik; Waterloo, Knut; Bråthen, Geir; Timón, Santiago; Aarsland, Dag; Fladby, Tormod; Kirsebom, Bjørn-Eivind (Journal article; Peer reviewed, 2021)
      The FAS phonemic fluency test is a commonly used neuropsychological test of executive function and processing speed. Although Norwegian discrete norms have been developed for the FAS test, American regression-based norms ...

    • Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients 

      Kirsebom, Bjørn-Eivind; Richter, Grit; Nordengen, Kaja; Aarsland, Dag; Bråthen, Geir; Tijms, Betty M; Visser, Pieter Jelle; Nilsson, Johanna; Selnes, Per; Kramberger, Milica G.; Winblad, Bengt; Waterloo, Knut; Gísladóttir, Berglind; Blennow, Kaj; Fladby, Tormod (Peer reviewed; Journal article, 2022)
      Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF ...